Механизм взаимодействия компонентов нового лекарственного покрытия медицинских стентов на основе поливинилпирролидона с введенными углеродными нанотрубками и лекарственными препаратами

Практически все используемые в России стенты с лекарственными покрытиями произведены за рубежом и имеют высокую стоимость, что не может удовлетворять потребностям российских пациентов и их финансовым возможностям. В связи с этим актуальным является поиск и разработка новых типов покрытий медицинских стентов, а также налаживание их производства в РФ. Необходимо создание тонкопленочных лекарственных покрытий стентов с увеличенным временем испускания лекарственного препарата для лечения различных заболеваний. В качестве компонента, обеспечивающего пролонгированную и дозированную десорбцию лекарственного препарата с поверхности стента, лучше всего использовать полимерный носитель. В работе исследована возможность применения перспективного материала современности – углеродных нанотрубок – в качестве компонента лекарственного покрытия медицинского стента, который обеспечит не только улучшение физико-механических свойств покрытия, но и пролонгированное действие лекарственного препарата за счет увеличения времени его десорбции. Выполнены теоретические исследования механизмов взаимодействия компонентов лекарственных покрытий стентов на основе биополимера поливинилпирролидона, в состав которых входят лекарственные препараты (тегафур, дексаметазон) и углеродные нанотрубки. Исследования выполнены в рамках квантово-химического расчетного метода теории функционала плотности (DFT), который широко используется во всем мире для расчета наносистем.

1. Seo EH, Na K. Polyurethane membrane with porous surface for controlled drug release in drug eluting stent. Biomaterials Research. 2014;18(1):15. DOI:10.1186/2055-7124-18-15

2. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome: Coronary Artery Disease. 2004;15(6):313-318. DOI:10.1097/00019501-200409000-00003

3. Mir SA, Hamid L, Bader GN, Shoaib A, et al. Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review. Molecules. 2022;27(19):6608. DOI:10.3390/molecules27196608

4. Paul A, Shao W, Shum-Tim D, Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles. Biomaterials. 2012;33(30):7655-7664. DOI:10.1016/j.biomaterials.2012.06.096

5. Patra JK, Das G, Fraceto LF, Campos EVR, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1):71. DOI:10.1186/s12951-018-0392-8

6. Hua S, De Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology. 2018;9:790. DOI:10.3389/fphar.2018.00790

7. Zvonareva DA, Zaporotskova IV, An EE, Chesheva MF. Investigation of the possibility of creating a drug coating for coronary stents based on chitosan and heparin. Interaction of ultrahigh frequency, terahertz and optical radiation with semiconductor micro- and nanostructures, metamaterials and biological objects: Collection of articles of the ninth All-Russian Scientific School-seminar, Saratov, May 24, 2022. Saratov: "Saratov source" Publ. house; 2022. p. 223-226.

8. Zaporotskova IV, Suchkov SG, Boroznin SV, Zvonareva DA, et al. Study of the possibility of creating a drug coating of biliary stents based on the copolymer "polylactic acid - polycaprolactone" modified with carbon nanotubes and doxorubicin. NBI technologies. 2023;17(2):18-26. DOI :10.15688/NBIT.jvolsu.2023.2.3 (In Russ.)

9. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. DOI: 10.3390/molecules25092193

10. Zhang X, Liu J, Li X, Li F, et al. Trastuzumabcoated nanoparticles loaded with docetaxel for breast cancer therapy. Dose-Response. 2019;17(3):155932581987258. DOI:10.1177/1559325819872583

11. Yao Y, Zhou Y, Liu L, Xu Y, et al. Nanoparticlebased drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences. 2020;7:193. DOI:10.3389/fmolb.2020.00193

12. Yokoyama S, Tamaru S, Tamaki S, Nakanishi D, et al. Genetic risk factors associated with antiemetic efficacy of palonosetron, aprepitant, and dexamethasone in japanese breast cancer patients treated with anthracyclinebased chemotherapy. Clinical Breast Cancer. 2018;18(2):e157-e165. DOI:10.1016/j.clbc.2017.05.013

13. Chen P-H, Jhou H-J, Chung C-H, Wu Y-Y, et al. Benefit of uracil–tegafur used as a postoperative adjuvant chemotherapy for stage IIA colon cancer. Medicina. 2022;59(1):10. DOI:10.3390/medicina59010010

14. Voronov VK, Kim D, Yanushkin AS, Gerashchenko LA. Properties and application of nanomaterials. Moscow: TNT LLC; 2012. 220 p. (In Russ.)

15. Kedik SA, Zhavoronok ES, Sedishev IP, Panov AV, et al. Polymers for sustained drug delivery systems with prolonged action (review). Promising synthetic and natural polymers. Razrabotka i registratsiya lekarstvennykh sredstv. 2013;2(3):18-26. (In Russ.)

16. Alekseev KV, Gritskova IA, Kedik SA. Polymers for pharmaceutical technology. Moscow: IFT Publ. house; 2011. 512 p. (In Russ.)

17. Phan DC, Goodwin DG, Frank BP, Bouwer EJ, et al. Biodegradability of carbon nanotube/polymer nanocomposites under aerobic mixed culture conditions. Science of the Total Environment. 2018;639:804-814. DOI: 10.1016/j.scitotenv.2018.05.137

18. Zaporotskova I, Kalinichenko V, Kozhitov L, Zaporotskov P, Kislova T. On the influence of carbon nanotubes on the physical and mechanical properties of polypropylene. NBI Technologies. 2021;15(2):27-36. DOI: 10.15688/NBIT.jvolsu.2021.2.5 (In Russ.)

19. Valeeva AA, Dekhtyar TF. Carbon nanotubes in medicine. Condensed matter physics and its applications: Proceedings of the IV International Scientific and Practical Conference, Sterlitamak, September 22-24, 2022. Sterlitamak: Bashkir State UniversityPubl. house; 2022. p. 467-469. (In Russ.)

20. Chernozatonsky LA, Sorokin PB. Carbon nanotubes: from fundamental research to nanotechnology. Moscow: Nauka; 2007. p. 154-174. (In Russ.)

21. Zaporotskova IV. Carbon and non-carbon nanomaterials and composite structures based on them: structure and electronic properties. Volgograd: Volgograd State University Publ. house; 2009. 488 p. (In Russ.)

22. Ermachenkova KY, Simakova EK. The structure of the cytostatic drugs group (classification). Innovations in science and practice: A collection of scientific articles based on the materials of the XII International Scientific and Practical Conference, Ufa, May 05, 2023. Volume Part 3. Ufa: Bulletin of Science LLC; 2023. p. 14-20. (In Russ.)

23. Cytostatics. Available from: https://www.euroonco.ru/preparations-from-a-z/citostatiki [Accessed 20 May 2024] (In Russ.)

24. Semenov NN, Vakhabova YuV. The role of the drug tegafur/uracil in the treatment of malignant tumors. Vmeste protiv raka: vracham vsekh spetsial′nostey. 2008;(1):20-25. (In Russ.)

25. Romanov BK, Dmitrieva NB, Zatsepilova TA. Antitumor drugs. Rossiyskiy meditsinskiy zhurnal. 2018;24(3):146-150. DOI:10.18821/0869-2106-2018-24-3-146-150 (In Russ.)

26. Kakora S, Ulanova T, Kotlyarov A, Korniletsky I, et al. Experience of using antimetabolic agents in the therapy of antitumor diseases. Mezhdunarodnyy nauchnoissledovatel′skiy zhurnal. 2023;4(130):52. DOI:10.23670/ IRJ.2023.130.35 (In Russ.)

27. Order of the Ministry of Health of the Russian Federation No. 103n dated February 28, 2019 "On approval of the procedure and deadlines for the development of clinical recommendations, their revision, the standard form of clinical recommendations and requirements for their structure, composition and scientific validity included in clinical recommendations", Appendix A3 "Reference materials, including compliance with indications for use and contraindications, methods of application and doses of medicines, instructions for the use of the drug". Available from: http://publication. pravo.gov.ru [Accessed 2 June 2024] (In Russ.)

28. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The New England Journal of Medicine. 2000;342(21):59. DOI:10.1056/NEJM200005253422102

29. Harousseau JL, Attal M, Leleu X, Troncy J, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498-505.

30. Koch WA. Chemist’s guide to density functional theory. Weinheim: Wiley-VCH; 2001. p. 19-28.

31. Elbakyan LS. Quantum chemical calculations using the GAUSSIAN software package and the GAUSSVIEW graphic. Volgograd: Volgograd State University Publ. house; 2022. 79 p. (In Russ.)

32. Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. A new ultrathin medicinal coating of medical stents: the mechanism of interaction and application technology. Methods of computer diagnostics in biology and medicine - 2021: collection of articles of the All-Russian School Seminar, Saratov, November 19, 2021. Saratov: "Saratovsky Istochnik" Publ. house; 2021. p. 49-52.

33. Zvonareva DA, An EE, Zaporotskova IV. New ultrathin medical coating of PVP-based medical biliary stents with addition of carbon nanotubes. AIP Conference Proceedings: The VII International Young Researchers’ Conference – Physics, Technology, Innovations (PTI-2020), 18 May 2020. Ekaterinburg: AIP Publishing. 2020;2313:080037. DOI: 10.1063/5.0032234

34. Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. Interaction mechanism and technology for application of new ultra-thin drug coating of medical biliary stents. NBI Technologies. 2022;(1):33-38. DOI:10.15688/NBIT.jvolsu.2022.1.6 (In Russ.)